Shares of Equillium Inc. gained 12.9% in premarket trading on Tuesday after the company shared a batch of interim data from an early stage trial evaluating its experimental treatment in 13 people with lupus nephritis. Equillium said 83% of the participants enrolled in the study achieved complete or partial response, and about two-thirds had a 80% reduction in urine protein creatinine ratio by week 28. The company expects to share topline data from the Phase 1b open-label proof-of-concept study for itolizumab in mid-2023. Equillium’s stock is down 48.8% this year, while the broader S&P 500 has declined 23.3%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.